Normal view

Received — 4 January 2026 ⏭ Favourites

npj Digital Medicine
A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer Yajiao Zhang · Haoran Zhang · Yanzhao Yang · Chao Wu · Lei Zhang · Wei Xia · Xue Wang · Xiaohuan Zhang · Lixiu Cao · Manju Liu · Jing Zhang · Fuhua Yan · Baiyong Shen · Ning Wen
npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer
31 December 2025 at 08:00

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer

By: Yajiao Zhang · Haoran Zhang · Yanzhao Yang · Chao Wu · Lei Zhang · Wei Xia · Xue Wang · Xiaohuan Zhang · Lixiu Cao · Manju Liu · Jing Zhang · Fuhua Yan · Baiyong Shen · Ning Wen

31 December 2025 at 08:00

npj Digital Medicine, Published online: 31 December 2025; doi:10.1038/s41746-025-02260-3

A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer

Nature Medicine
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial Benjamin L. Musher · Spyridoula Vasileiou · Brandon G. Smaglo · Catherine S. Robertson · Mengfen Wu · Tao Wang · Ayumi Watanabe · Manik Kuvalekar · Yovana Velazquez · Shamika Ketkar · Tamadar Al Doheyan · Penelope G. Papayanni · Aakash Shah · Natalia Lapteva · Bambi J. Grilley · George Van Buren · Premal D. Lulla · Helen E. Heslop · Cliona M. Rooney · Malcolm K. Brenner · Ann M. Leen
Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.
2 January 2026 at 08:00

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

Nature Medicine

By: Benjamin L. Musher · Spyridoula Vasileiou · Brandon G. Smaglo · Catherine S. Robertson · Mengfen Wu · Tao Wang · Ayumi Watanabe · Manik Kuvalekar · Yovana Velazquez · Shamika Ketkar · Tamadar Al Doheyan · Penelope G. Papayanni · Aakash Shah · Natalia Lapteva · Bambi J. Grilley · George Van Buren · Premal D. Lulla · Helen E. Heslop · Cliona M. Rooney · Malcolm K. Brenner · Ann M. Leen

2 January 2026 at 08:00

Nature Medicine, Published online: 02 January 2026; doi:10.1038/s41591-025-04043-5

Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.